BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

944 related articles for article (PubMed ID: 18051714)

  • 1. [Application of high-risk human papillomavirus testing in women with abnormal cytology].
    Ou H; Bian ML; Zhang XY; Chen QY; Li M; Chen Y; Liu J
    Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2007 Oct; 29(5):608-11. PubMed ID: 18051714
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Distribution of human papillomavirus types in ThinPrep Papanicolaou tests classified according to the Bethesda 2001 terminology and correlations with patient age and biopsy outcomes.
    Evans MF; Adamson CS; Papillo JL; St John TL; Leiman G; Cooper K
    Cancer; 2006 Mar; 106(5):1054-64. PubMed ID: 16421920
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Evaluation of CIN2+ /CIN3+ risk of different HPV subtypes infection combined with abnormal cytology status].
    Luo HX; Du H; Liu ZH; Zhang LJ; Wang C; Wu RF
    Zhonghua Zhong Liu Za Zhi; 2018 Mar; 40(3):232-238. PubMed ID: 29575846
    [No Abstract]   [Full Text] [Related]  

  • 4. [Use of high-risk human papillomavirus DNA testing to deal with atypical squamous cells undetermined significance and low squamous intraepithelial lesion].
    Guo YL; You K; Geng L; Zhang XW; Shen XY; Yao YJ; Fan XH
    Beijing Da Xue Xue Bao Yi Xue Ban; 2006 Oct; 38(5):480-2. PubMed ID: 17068618
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Introduction of liquid-based cytology and human papillomavirus testing in cervical cancer screening in Luxembourg.
    Latsuzbaia A; Hebette G; Fischer M; Arbyn M; Weyers S; Vielh P; Schmitt F; Mossong J
    Diagn Cytopathol; 2017 May; 45(5):384-390. PubMed ID: 28247516
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Significance of high-risk human papillomavirus DNA detection in women 50 years and older with squamous cell papanicolaou test abnormalities.
    Zhao C; Zhao S; Heider A; Austin RM
    Arch Pathol Lab Med; 2010 Aug; 134(8):1130-5. PubMed ID: 20670132
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Atypical squamous cells, cannot exclude high-grade squamous intraepithelial lesion: diagnostic performance, human papillomavirus testing, and follow-up results.
    Srodon M; Parry Dilworth H; Ronnett BM
    Cancer; 2006 Feb; 108(1):32-8. PubMed ID: 16136595
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Performance of HPV DNA testing with hybrid capture 2 in triaging women with minor cervical cytologic abnormalities (ASC-US/LSIL) in Northern Thailand.
    Khunamornpong S; Settakorn J; Sukpan K; Srisomboon J; Suprasert P; Siriaunkgul S
    Asian Pac J Cancer Prev; 2014; 15(24):10961-6. PubMed ID: 25605209
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [HPV E6 and E7 mRNA combined with HPV 16 and 18 or 45 genotyping testing as a means of cervical cancer opportunistic screening].
    Wang JJ; Dong J; Deng ZX; Wang PF; Zhang XX; Du Y
    Zhonghua Fu Chan Ke Za Zhi; 2019 May; 54(5):301-306. PubMed ID: 31154710
    [No Abstract]   [Full Text] [Related]  

  • 10. Reflex high-risk human papilloma virus DNA test is useful in the triage of women with atypical squamous cells cannot exclude high-grade squamous intraepithelial lesion.
    Wu HH; Allen SL; Kirkpatrick JL; Elsheikh TM
    Diagn Cytopathol; 2006 Oct; 34(10):707-10. PubMed ID: 16955480
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Role of p16(INK4a) cytology testing as an adjunct to enhance the diagnostic specificity and accuracy in human papillomavirus-positive women within an organized cervical cancer screening program.
    Gustinucci D; Passamonti B; Cesarini E; Butera D; Palmieri EA; Bulletti S; Carlani A; Staiano M; D'Amico MR; D'Angelo V; Di Dato E; Martinelli N; Malaspina M; Spita N; Tintori B; Fulciniti F
    Acta Cytol; 2012; 56(5):506-14. PubMed ID: 23075891
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Combining high-risk human papillomavirus DNA test and cytological test to detect early cervical dysplasia].
    Qian DY; Cen JM; Wang D; Zeng RH; Lin AH; Shu YH; Hong DH; Huang ZH
    Zhonghua Fu Chan Ke Za Zhi; 2006 Jan; 41(1):34-7. PubMed ID: 16635326
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Clinical value of p16
    Song FB; Du H; Xiao AM; Wang C; Huang X; Yan PS; Liu ZH; Qu XF; Belinson JEROMEL; Wu RF
    Zhonghua Fu Chan Ke Za Zhi; 2020 Nov; 55(11):784-790. PubMed ID: 33228350
    [No Abstract]   [Full Text] [Related]  

  • 14. Liquid-based cytology and human papillomavirus testing: a pooled analysis using the data from 13 population-based cervical cancer screening studies from China.
    Pan QJ; Hu SY; Guo HQ; Zhang WH; Zhang X; Chen W; Cao J; Jiang Y; Zhao FH; Qiao YL
    Gynecol Oncol; 2014 May; 133(2):172-9. PubMed ID: 24631450
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Human papillomavirus testing versus repeat cytology for triage of minor cytological cervical lesions.
    Arbyn M; Roelens J; Simoens C; Buntinx F; Paraskevaidis E; Martin-Hirsch PP; Prendiville WJ
    Cochrane Database Syst Rev; 2013 Mar; 2013(3):CD008054. PubMed ID: 23543559
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Liquid-based cytology--new possibilities in the diagnosis of cervical lesions.
    Juric D; Mahovlić V; Rajhvajn S; Ovanin-Rakić A; Skopljanac-Macina L; Barisić A; Projić IS; Babić D; Susa M; Corusić A; Oresković S
    Coll Antropol; 2010 Mar; 34(1):19-24. PubMed ID: 20432728
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cytology and high risk HPV testing in cervical cancer screening program: Outcome of 3-year follow-up in an academic institute.
    Yang J; Nolte FS; Chajewski OS; Lindsey KG; Houser PM; Pellicier J; Wang Q; Ehsani L
    Diagn Cytopathol; 2018 Jan; 46(1):22-27. PubMed ID: 29048733
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Human papillomavirus testing using hybrid capture II with SurePath collection: initial evaluation and longitudinal data provide clinical validation for this method.
    Ko V; Tambouret RH; Kuebler DL; Black-Schaffer WS; Wilbur DC
    Cancer; 2006 Dec; 108(6):468-74. PubMed ID: 17091508
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Risks of CIN 2+, CIN 3+, and Cancer by Cytology and Human Papillomavirus Status: The Foundation of Risk-Based Cervical Screening Guidelines.
    Demarco M; Lorey TS; Fetterman B; Cheung LC; Guido RS; Wentzensen N; Kinney WK; Poitras NE; Befano B; Castle PE; Schiffman M
    J Low Genit Tract Dis; 2017 Oct; 21(4):261-267. PubMed ID: 28953116
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The clinician's view: role of human papillomavirus testing in the American Society for Colposcopy and Cervical Pathology Guidelines for the management of abnormal cervical cytology and cervical cancer precursors.
    Cox JT;
    Arch Pathol Lab Med; 2003 Aug; 127(8):950-8. PubMed ID: 12952506
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 48.